Volume 23 - Issue 12 - December 2015
Feature
NPF Endorsed Features
12/18/2015
New research finds the incidence of psoriatic arthritis (PsA) among patients with psoriasis is much greater than previously thought.
New research finds the incidence of psoriatic arthritis (PsA) among patients with psoriasis is much greater than previously thought.
New research finds the incidence...
12/18/2015
The Dermatologist
NPF Endorsed Features
12/18/2015
This article reviews the current biologic therapies for the treatment of psoriasis and psoriatic arthritis, discusses the importance of patient and clinician education in the decision-making process and highlights drugs in the...
This article reviews the current biologic therapies for the treatment of psoriasis and psoriatic arthritis, discusses the importance of patient and clinician education in the decision-making process and highlights drugs in the...
This article reviews...
12/18/2015
The Dermatologist
12/18/2015
In this excerpt from the recently published book, Practical Psoriasis Management, the author discusses the use of apremilast for moderate-to-severe psoriasis.
In this excerpt from the recently published book, Practical Psoriasis Management, the author discusses the use of apremilast for moderate-to-severe psoriasis.
In this excerpt from the...
12/18/2015
The Dermatologist
12/16/2015
Posters from the Fall clinical conference look at patient experiences with psoriasis, as well as therapies for this common chronic skin disease.
Posters from the Fall clinical conference look at patient experiences with psoriasis, as well as therapies for this common chronic skin disease.
Posters from the Fall clinical...
12/16/2015
The Dermatologist
12/16/2015
FEATURES
JANUARY – VOLUME 23, ISSUE 1
Business Insider Series: Leveraging Aesthetic Devices in Your Practice
No. 1, p. 22
Exploring Aesthetic Interventions: Fat Transfer for Mid-Face Lipoatrophy
No. 1, p. 30
Clinical Insights on...
FEATURES
JANUARY – VOLUME 23, ISSUE 1
Business Insider Series: Leveraging Aesthetic Devices in Your Practice
No. 1, p. 22
Exploring Aesthetic Interventions: Fat Transfer for Mid-Face Lipoatrophy
No. 1, p. 30
Clinical Insights on...
FEATURES
JANUARY – VOLUME 23,...
12/16/2015
The Dermatologist
Column
Therapeutic Review
12/16/2015
Researchers conducted a retrospective analysis of a group of adolescents (age <17 years) and children with plaque psoriasis treated with cyclosporine at multiple dermatology clinics in Italy. They set out to evaluate the efficacy and...
Researchers conducted a retrospective analysis of a group of adolescents (age <17 years) and children with plaque psoriasis treated with cyclosporine at multiple dermatology clinics in Italy. They set out to evaluate the efficacy and...
Researchers conducted a...
12/16/2015
The Dermatologist
Voices
12/16/2015
The recent approval of an injectable for submental fat has brought more men into the clinic.
The recent approval of an injectable for submental fat has brought more men into the clinic.
The recent approval of an...
12/16/2015
The Dermatologist
Chief Medical Editor Message
12/16/2015
Humans tolerate (perhaps even pursue) work, as long as that work has meaning. Fortunately for us dermatologists, our work is tremendously meaningful, changing the lives of patients. We are at the frontlines, and can see the benefit of what we...
Humans tolerate (perhaps even pursue) work, as long as that work has meaning. Fortunately for us dermatologists, our work is tremendously meaningful, changing the lives of patients. We are at the frontlines, and can see the benefit of what we...
Humans tolerate (perhaps even...
12/16/2015
The Dermatologist
Department
Board Review
12/16/2015
1. Immunohistochemical staining shows strong reactivity for the p53 protein. The most likely diagnosis is:
1. Immunohistochemical staining shows strong reactivity for the p53 protein. The most likely diagnosis is:
1. Immunohistochemical...
12/16/2015
The Dermatologist
News
News
12/16/2015
Nivolumab (Opdivo, Bristol-Myers Squibb Company) injection received FDA approval for intravenous use as a single agent for the treatment of patients with BRAF V600 wild-type (WT) unresectable or metastatic melanoma.
Nivolumab (Opdivo, Bristol-Myers Squibb Company) injection received FDA approval for intravenous use as a single agent for the treatment of patients with BRAF V600 wild-type (WT) unresectable or metastatic melanoma.
Nivolumab (Opdivo, Bristol-Myers...
12/16/2015
The Dermatologist
